Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2807-2812

  Nukatsuka, Mamoru ^a   Saito, Hitoshi ^a   Sakamoto, Kazuki ^b   Nakagawa, Fumio ^a   Uchida, Junji ^a   Kobunai, Takashi ^d   Shiraishi, Kazuyoshi ^c   Takechi, Teiji ^d  

^a Tokushima Research Center   (Japan)

^b Tsukuba Research Center   (Japan)

^c Department of Product Lifecycle Management ^*  (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Capecitabine; COL 1 cells; Colorectal cancer; COX; Growth delay period; Oxaliplatin; S 1

Indexed keywords

CAPECITABINE; COLLAGEN TYPE 1; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONCENTRATION RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; TEGAFUR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865682932     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M and Rougier P: CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A : 1283-1287, 1995.
2. Diaz-Rubio E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist 9: 282-294, 2004.
3. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N and Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21: 2059-2069, 2003. (Pubitemid 46606353)
4. Meyerhardt JA, Stuart K, Fuchs CS, Zhu AX, Earle CC, Bhargava P, Blaszkowsky L, Enzinger P, Mayer RJ, Battu S, Lawrence C and Ryan DP: Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 18 : 1185-1189, 2007. (Pubitemid 47244364)
5. Boccia RV, Cosgriff TM, Headley DL, Badarinath S and Dakhil SR: A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 9 : 102-107, 2010.
6. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M and Gansert J: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
7. Shiroiwa T, Fukuda T and Tsutani K: Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 101: 12-18, 2009.
8. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ; AIO Colorectal Study Group: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007. (Pubitemid 47548561)
9. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5- chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996. (Pubitemid 26171684)
10. Fukushima M, Satake H, Uchida J, Shimamoto Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13: 693-698, 1998.
11. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
12. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi: Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000.
13. Saeki T, Takashima S, Sano M, Noboru Horikoshi N, Miura S, Shimizu S., Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S and Taguchi T: A Phase II Study of S-1 in Patients with Metastatic Breast Cancer - a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11: 194-202, 2002.
14. Nakashima K, Hironaka S, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Yasui H, Taku K, Kojima T and Machida N: Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. Jpn J Clin Oncol 38: 810-815, 2008.
15. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, Shirao K, Matsumura Y and Gotoh M: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003. (Pubitemid 38168001)
16. Muro K, Boku N, Shimada Y, Tsuji A, Sameshima S, Baba H, Satoh T, Denda T, Ina K, Nishina T, Yamaguchi K, Takiuchi H, Esaki T, Tokunaga S, Kuwano H, Komatsu Y, Watanabe M, Hyodo I, Morita S and Sugihara K: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol 11: 853-860, 2010.
17. Siler K, Eggensperger D, Hand PH, Milenic DE, Miller LS, Houchens DP, Hinkle G and Schlom J: Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther 4: 163-181, 1993. (Pubitemid 23333065)
18. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
19. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I and Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34 : 1274-1281, 1998. (Pubitemid 28342121)
20. Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P and Allal C: In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different levels of EGFR. Cancer Chemother Pharmacol 7: 709-718, 2006.
21. Bauer P, Röhmel J, Maurer W and Hothorn L: Testing strategies in multi-dose experiments including active control. Stat Med 17: 2133-2146, 1988.
22. Park YS, Lim HY, Lee J, Kim TW, Lee J, Hong YS, Kim SY, Baek JY, Kim JH, Lee K, Chung I, Cho S, Lee KH, Shin SJ, Kang HJ, Shin D, Jo SJ, Lee JW: A randomized phase III study of SOX (S-1/oxaliplatin) versus COX (capecitabine/oxaliplatin) in patients with advanced colorectal cancer. J Clin Oncol 29: abstract #3524, 2011.
23. Sharif S, O'Connell MJ, Yothers G, Lopa S and Wolmark N: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26: 956-963, 2008.
24. Zhao G, Gao P, Yang KH, Tian JH and Ma B: Capecitabine/ oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. Colorectal Dis 12 : 615-623, 2010.
25. Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F and Taguchi T: Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep 24: 835-842 2010.
26. Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, Yoshida T, Hatashita E, Yamada Y, Satoh T, Tamura K, Fukuoka M and Nakagawa K: Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase. Mol Cancer Ther 7: 599-606, 2008. (Pubitemid 351492458)
27. Réjiba S, Bigand C, Parmentier C and Hajri A: Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK: UMK GDEPT and TS/RR siRNA strategies. Neoplasia 11 : 637-650, 2009.
28. Hasegawa M, Miyajima A, Kosaka T, Yasumizu Y, Tanaka N, Maeda T, Shirotake S, Ide H, Kikuchi E and Oya M: Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration-resistant prostate cancer. Int J Cancer 130: 431-442, 2012.
29. Yeh KH, Cheng AL, Wan JP, Lin CS and Liu CC: Down-regulation of thymidylate synthase expression and its steadystate mRNA by oxaliplatin in colon cancer cells. Anticancer Drugs 15: 371-736, 2004.
30. Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ and Ladner RD: Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatininduced DNA damage. Nucleic Acids Res 37: 78-95, 2009.
31. Yonekura K, Basaki Y, Chikahisa L, Okabe S, Hashimoto A, Miyadera K, Wierzba K and Yamada Y: UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res 5 : 2185-2191, 1999. (Pubitemid 29399276)
32. Ooyama A, Oka T, Zhao HY, Yamamoto M, Akiyama S and Fukushima M: Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 18: 26-36, 2008.
33. Harada K, Supriatno, Kawashima Y, Yoshida H and Sato M: S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2. Int J Oncol 30: 365-374, 2007.